Monitor the sBLA submission by year-end 2026 and FDA acceptance/priority review decision. Full study details at an upcoming medical congress may provide additional efficacy and durability data. The expanded addressable population (BCG-naive) represents a much larger market than the current BCG-unresponsive indication.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $7.11entry
- T+1 · 7d ago −5.13%α −4.77% · $6.75
- T+5 · 17h ago −15.89%α −14.20% · $5.98
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ImmunityBio announced positive final analysis results from the QUILT-2.005 trial, showing ANKTIVA plus BCG met the primary efficacy endpoint in BCG-naive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ. The chemotherapy-free combination demonstrated a statistically significant improvement over BCG alone. A supplemental BLA submission to the FDA remains on track for year-end 2026, potentially expanding ANKTIVA's approved indication to earlier-stage patients.
Key Facts
- ANKTIVA plus BCG met the primary efficacy endpoint in Cohort A of the randomized registrational QUILT-2.005 trial in BCG-naive NMIBC patients with CIS
- The combination demonstrated a statistically significant improvement in efficacy compared with BCG alone
- Trial enrolled 370 randomized patients across over 75 clinical trial sites
- Database lock occurred on October 20, 2026
- Supplemental BLA submission to FDA remains on track for year-end 2026
- No treatment-related deaths were reported; safety profile consistent with BCG alone
- Median duration of response had not yet been reached with ANKTIVA plus BCG
- ANKTIVA was previously approved in April 2024 for BCG-unresponsive NMIBC CIS, with indication expanded in October 2026
Financial Impact
Positive Phase 3 readout for a registrational trial in a larger addressable patient population (BCG-naive vs. BCG-unresponsive) could significantly expand ANKTIVA's commercial opportunity, though no financial figures were disclosed
Risk Factors
- sBLA submission or FDA review may be delayed or result in a non-approval decision
- Open-label trial design may introduce bias; final results could change with longer follow-up
- Competition from existing and future therapies for BCG-naive NMIBC
- Manufacturing and supply risks, including BCG availability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001326110-26-000091 |
| Document: ibrx-20261109.htm | 0001326110-26-000091 |
| Document: 0001326110-26-000091-index-headers.html | 0001326110-26-000091 |
| Document: 0001326110-26-000091-index.html | 0001326110-26-000091 |
| Document: 0001326110-26-000091.txt | 0001326110-26-000091 |
Track record
11 reports on IBRX
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +19.12% at T+60 after the Apr 9, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $7.11 Now $5.98 −15.89% settles Feb 5
- Nov 9, 20267d ago 8-K Bullish 6/10 Viewing Entry $7.11 Now $5.98 −15.89% settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $8.93 Now $5.98 −33.03% settles Feb 2
- Oct 14, 20264w ago 8-K Bullish 7/10 Entry $10.00 Now $5.98 −40.20% settles Jan 12
- Aug 4, 202614w ago 8-K Neutral 5/10 Entry $6.95 to $8.63 Now $5.98 −13.96% ▲ +24.17% +24.39% vs SPY
- Jul 6, 202619w ago Insider Cluster Neutral 2/10 Entry $8.76 to $9.44 Now $5.98 −31.74% ▲ +7.76% +5.77% vs SPY
- Jul 1, 202619w ago Insider Cluster Neutral 2/10 Entry $9.44 to $8.52 Now $5.98 −36.65% ▼ −9.75% −12.54% vs SPY
- May 18, 202626w ago 8-K Bullish 5/10 Entry $7.76 to $7.65 Now $5.98 −22.94% ▼ −1.42% −7.71% vs SPY
- Apr 9, 202631w ago 8-K Bullish 8/10 Entry $7.48 to $8.91 Now $5.98 −20.05% ▲ +19.12% +8.34% vs SPY
- Apr 6, 202632w ago 8-K Neutral 4/10 Entry $7.08 to $9.20 Now $5.98 −15.54% ▲ +29.94% +16.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers